CONTENTS:
- Supporting economically disadvantaged tobacco users to help them stop: time to review priorities? [Editorial]. Siddiqi K., p. 1221-1222.
- Nicotine vaccination - does it have a future? [Editorial]. van Schayck O.C.P., Horstman K., Vuurman E., de Wert G., Kotz D., p. 1223-1225.
- The 'drug policy ratchet': why do sanctions for new psychoactive drugs typically only go up? [For debate]. Stevens A., Measham F., p. 1226-1232.
- Vice ratchets [Comment]. Caulkins J.P., p. 1233-1234.
- New evidence on the tenuous state of evidence-based drug policy [Comment]. MacCoun R.J., p. 1234-1235.
- Widening the debate on the drug policy ratchet: response to commentaries. Measham F., Stevens A., p. 1235-1236.
- Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment [For debate]. Darke S., Farrell M., p. 1237-1242.
- Legislative strategies other than legalizing illicit opioids may help to reduce overdose fatalities [Comment]. Trafton J.A., Oliva E.M., p. 1243-1244.
- Addiction Research Centres and the Nurturing of Creativity. Bühringer G., p. 1245-1251.
- Efficacy of the nicotine vaccine 3′-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial. Hoogsteder P.H.J., Kotz D., van Spiegel P.I., Viechtbauer W., van Schayck O.C.P., p. 1252-1259.
- Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task. Havermans A., Vuurman E.F., van den Hurk J., Hoogsteder P., van Schayck O.C.P., p. 1260-1267.
- Vaccination against smoking: an annotated agenda for debate. A review of scientific journals, 2001-13. Wolters A., de Wert G., van Schayck O.C.P., Horstman K., p. 1268-1273.
- Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Garbutt J.C., Greenblatt A.M., West S.L., Morgan L.C., Kampov-Polevoy A., Jordan H.S., et al., p. 1274-1284.
- Commentary on Garbutt et al. (2014): Can we predict who benefits from naltrexone in the treatment of alcohol dependence? Kranzler H.R., p. 1285-1286.
- Sustaining motivational interviewing: a meta-analysis of training studies. Schwalbe C.S., Oh H.Y., Zweben A., p. 1287-1294.
- Commentary on Schwalbe et al. (2014): Two wishes for the future of motivational interviewing - workshops with fewer learning targets and sustainable coaching. Dunn C., Darnell D., p. 1295-1296.
- The impact of alcohol on clinical outcomes in established psychosis: a longitudinal study. Barrowclough C., Eisner E., Bucci S., Emsley R., Wykes T., p. 1297-1305.
- The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Degenhardt L., Larney S., Kimber J., Gisev N., Farrell M., Dobbins T., et al., p. 1306-1317.
- Commentary on Degenhardt et al. (2014): Access to opioid substitution therapy in prison is not enough - the crucial role of post-release retention in preventing drug-related harms. Stoové M., Kinner S., p. 1318-1319.
- The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Degenhardt L., Charlson F., Mathers B., Hall W.D., Flaxman A.D., Johns N., et al., p. 1320-1333.
- Commentary on Degenhardt et al. (2014): Regional variation in the global burden of disease attributable to opioid dependence - where do the data come from and does population size matter? Hser Y.-I., Evans E., Grella C., p. 1334-1335.
- Response to Hser et al. (2014): The necessity for more and better data on the global epidemiology of opioid dependence. Degenhardt L., Mathers B., Hall W.D., p. 1335-1337.
- Spatial differences and temporal changes in illicit drug use in Europe quantified by wastewater analysis. Ort C., van Nuijs A.L.N., Berset J.-D., Bijlsma L., Castiglioni S., Covaci A., et al., p. 1338-1352.
- Commentary on Ort et al. (2014): What next to deliver on the promise of large scale sewage-based drug epidemiology? Bruno R., Hall W., Kirkbride K.P., Lai F.Y., O'Brien J.W., Prichard J., et al., p. 1353-1354.
- Using cognitive modelling to investigate the psychological processes of the Go/NoGo discrimination task in male abstinent heroin misusers. Liang C.-W., Zhong R.Y.-X., Chung Y.-C., Pan C.-H., Yen M.-Y., Cheng C.-P., et al., p. 1355-1362.
- Effects of depressive symptoms on antecedents of lapses during a smoking cessation attempt: an ecological momentary assessment study. Brodbeck J., Bachmann M.S., Brown A., Znoj H.J., p. 1363-1370.
- Youth tobacco use type and associations with substance use disorders. Cavazos-Rehg P.A., Krauss M.J., Spitznagel E.L., Grucza R.A., Bierut L.J., p. 1371-1380.
- Inaccuracies in editorial by Babor & Miller. Ellison R.C., p. 1381-1382.
- Response to Babor & Miller Editorial 'McCarthyism, conflict of interest and Addiction's new transparency declaration procedures'. Conibear H., p. 1382-1383.
- Reply to Conibear (2014). Babor T.F., Miller P.G., p. 1383-1384.
- Youth alcohol polarization effects in regional but not national data. Hallgren M., p. 1384-1385.
- No polarization in youth drinking in Stockholm county: response to Hallgren. Norström T., Svensson J., p. 1385-1386.